Justia Products Liability Opinion Summaries

Articles Posted in US Court of Appeals for the Second Circuit
by
Plaintiff RSD Leasing Inc., a company that leases and, eventually, resells trucks to other commercial entities, appealed from a district court decision, granting in relevant part summary judgment to Defendants Navistar International Corp. and Navistar, Inc., the manufacturer of several allegedly substandard trucks in RSD’s fleet. The sole question on appeal is whether, for purposes of its purchase of those trucks, RSD qualifies as a “consumer” under the Vermont Consumer Protection Act and therefore is eligible to invoke the Act’s protections. In the absence of any on-point Vermont caselaw signaling whether the statute extends “consumer” protections to a business that purchases a good intending exclusively to lease that good to a third party and then to resell it at the end of the lease term, the district court relied in substantial part on two brief passages from the Act’s legislative history, holding that RSD was not acting as a “consumer” when it purchased the trucks at issue.   The Second Circuit wrote that it is unable to confidently predict how the Vermont Supreme Court would decide the matter. Therefore, the court certified to the Vermont Supreme Court the following question: Does a business that purchases goods intending first to lease those goods to end users and then to resell them at the termination of the lease term qualify as a ‘consumer’ under the VCPA? View "RSD Leasing, Inc. v. Navistar Int'l Corp." on Justia Law

by
The National Advertising Division (“NAD”), a self-regulatory organization, concluded that Defendant Young Living Essential Oils, LC’s (“Young Living”) claims that its oils are “therapeutic-grade” and impart physical and/or mental health benefits are “unsupported,” and recommended that Young Living stop making these claims. Plaintiff had already spent money on Young Living’s products, including lavender oil advertised to “promote [a] feeling of calm and fight occasional nervous tension” and peppermint oil that allegedly “helps to  maintain energy levels.” Feeling misled by claims that the products would have effects like “promoting feelings of relaxation & tranquility,” Plaintiff sued, on behalf of herself and other similarly situated individuals, asserting claims under common law and various state statutes that she believes protect consumers like her against companies like Young Living. The district court dismissed Plaintiff’s suit, finding that Young Living’s claims that its products would do things like “help to maintain energy levels” was run-of-the-mill puffery that companies use when trying to persuade potential customers to part with their dollars.   The Second Circuit vacated in part and affirmed in part. The court vacated the district court’s ruling insofar as it dismissed the New York General Business Law claims for being based on statements of non-actionable puffery and the unjust enrichment claim for not satisfying the Rule 9(b) requirement. The court affirmed the ruling as to the dismissal of the breach of warranty claims. The court found that Plaintiff’s stated the circumstances constituting fraud with sufficient particularity to satisfy Rule 9(b) and certainly with enough particularity to give fair notice of her claim and enable the preparation of a defense. View "MacNaughton v. Young Living Essential Oils, LC" on Justia Law

by
Plaintiffs appealed from a district court judgment dismissing, as preempted by the federal Food, Drug, and Cosmetic Act (“FDCA”), their claims under the Connecticut Product Liability Act (“CPLA”) for injuries caused by a medical device, and denying leave to amend the complaint to include a claim under the Connecticut Unfair Trade Practices Act (“CUTPA”).   Because both issues turned on unresolved questions of state law, the Second Circuit certified two questions to the Supreme Court of Connecticut to clarify the scope of the CPLA and CUPTA. In view of the Connecticut Supreme Court’s answers to those questions, the court held: (1) that the Plaintiffs’ CPLA claims are not preempted by the FDCA because traditional Connecticut tort law provides a cause of action for failing to provide adequate warnings to regulators such as the United States Food and Drug Administration; and (2) that Plaintiffs’ proposed CUTPA claim would be precluded by the CPLA.   Accordingly, the court vacated the district court’s dismissal of the CPLA claims, affirm the district court’s denial of leave to amend the complaint, and remanded for further proceedings. View "Glover v. Bausch & Lomb, Inc." on Justia Law

by
In 1974, when Sarkees was 19, he worked for Goodyear for seven months. Sarkees believed he was exposed to the chemical ortho-toluidine (OT). He took chemical samples and unloaded railroad tank cars, the majority of which contained OT, he drove a forklift to load Nailax2 (made with OT), and he manually cleaned Nailax reactors and packaged Nailax. While conducting many of these tasks, Sarkees recognized the smell of OT and experienced chemicals splashing on his skin. He often cleaned the inside of Nailax reactors, wearing “the same contaminated coveralls for the entire work shift.” Sarkees approximated that he cleaned the filters “more than 80 times,” inhaling a “strong chemical smell” and fumes without a respirator. A 2014 Department of Health and Human Services report states, “Epidemiological studies have demonstrated a causal relationship between exposure to o-toluidine and urinary-bladder cancer in humans.” Beginning in 1998, Sarkees participated in a bladder cancer screening program offered by Goodyear to former employees. In 2016, he was diagnosed with bladder cancer.The district court dismissed his suit for negligence and strict products liability, after excluding expert testimony that OT was the specific cause of his cancer. The Second Circuit vacated. In excluding the expert’s opinion, the district court improperly relied on a state court evidence ruling instead of the applicable federal evidence rule. The evidence is admissible under Federal Rule 702 and “Daubert.” View "Sarkees v. E. I. DuPont de Nemours and Co." on Justia Law

by
After plaintiff suffered post-operative injuries following implantation of artificial lenses during cataract surgery, she and her husband filed suit against Bausch & Lomb, the manufacturer of the lenses, as well as related entities. On appeal, plaintiff challenged the district court's grant of defendants' motion to dismiss the negligence and failure-to-warn claims and denial of the motion for leave to amend the complaint to add a claim based on wrongful marketing.The Second Circuit reserved decision and certified two questions to the Supreme Court of Connecticut: 1) Whether a cause of action exists under the negligence or failure-to-warn provisions of the Connecticut Product Liability Act, Conn. Gen. Stat. 52-572h, 52-572q, or elsewhere in Connecticut law, based on a manufacturer's alleged failure to report adverse events to a regulator like the FDA following approval of the device, or to comply with a regulator's post-approval requirements. 2) Whether the Connecticut Product Liability Act's exclusivity provision, Conn. Gen. Stat. 52-572n, bars a claim under the Connecticut Unfair Trade Practices Act, Conn. Gen. Stat. 42-110a, et seq., based on allegations that a manufacturer deceptively and aggressively marketed and promoted a product despite knowing that it presented a substantial risk of injury. View "Glover v. Bausch & Lomb, Inc." on Justia Law

by
The Second Circuit affirmed the district court's grant of summary judgment in favor of defendants and dismissal of plaintiffs' products liability claims after precluding, pursuant to Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), the opinions of plaintiffs' expert witnesses as to general causation.The court concluded that, not only was it appropriate for the district court to take a hard look at plaintiffs' experts' reports, the court was required to do so to ensure reliability. Furthermore, plaintiffs' contention that the district court impermissibly focused on plaintiffs' experts' conclusions instead of their methodologies is similarly unavailing. Even assuming that the district court required experts to back their opinions with studies definitely supporting their conclusions, the district court did not err in doing so. Therefore, the district court appropriately undertook a rigorous review of each of plaintiffs' experts, and based on that review reasonably found that the experts' methods were not sufficiently reliable and that their conclusions were not otherwise supported by the scientific community.The court also concluded that the district court correctly granted summary judgment in favor of defendants where no reasonable juror could find that it was more likely than not that general causation had been established based on plaintiffs' admissible evidence. The court was not persuaded that the district court erred in holding that there is a general causation requirement across all states. Furthermore, the court rejected plaintiffs' contention that the district court prevented them from obtaining and presenting evidence of general causation. In this case, plaintiffs failed to explain how admitting portions of the expert reports would have established general causation; the district court did not abuse its broad discretion in excluding differential-diagnosis evidence; and the district court did not abuse its broad discretion in managing discovery. View "In Re: Mirena IUS Levonorgestrel-Related Products Liability Litigation" on Justia Law

by
Plaintiff filed suit against Philip Morris under the Connecticut Product Liability Act, alleging that the company's Marlboro and Marlboro Lights cigarettes were negligently designed and caused his wife's death. After a jury found for Philip Morris, plaintiff appealed.The Second Circuit held that, although the district court misapplied the nonmutual offensive collateral estoppel standard, the error did not necessarily require vacatur of the judgment. Therefore, the court remanded and directed the district court to consider whether the application of nonmutual offensive collateral estoppel would be unfair. View "Bifolck v. Philip Morris USA Inc." on Justia Law